Interface Biologics licenses Endexo to Fresenius
July 20, 2010 by stephenkilmer · Leave a Comment
Closely held Interface Biologics of Toronto has signed an evaluation and exclusive license option agreement with Germany’s Fresenius Medical Care (FSE:FME; NYSE:FMS), the world’s largest provider of dialysis products and services. Under the accord, Fresenius will evaluate the use and efficacy of Interface’s Endexo technology to various components of its dialysis circuits for treating end-stage [...]
Listen to BioTuesdays 
